PressAugust 28, 2024 Revive Therapeutics Provides (Yet Another) Update on Bucillamine for Nerve Agent Exposure
PressAugust 28, 2024 Optimi Health & ATMA Receive No Objection Letter from Health Canada for Phase 2 Clinical Trial
PressAugust 28, 2024 PharmaDrug’s Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases
PressAugust 27, 2024 Psilera Receives Positive Preclinical in Vivo Data for Frontotemporal Dementia (FTD) Candidate, PSIL-006
PressAugust 27, 2024 BetterLife Highlights Advantages of Non-hallucinogenic LSD Derivative BETR-001 and Publication of its Methods to Treat Mood Disorders Patent
PressAugust 23, 2024 Revitalist Lifestyle and Wellness Ltd. Sponsors The American Legion 105th National Convention to Combat Veteran Suicide
PressAugust 23, 2024 PharmaDrug’s Sairiyo Therapuetics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins
PressAugust 22, 2024 Bright Green Embarks on Major Partnership With Benuvia Pharmaceuticals Will Supply Pharma Expert With American Made Raw Materials From Its Industry Leading and DEA-Approved SCH I & II Drug Facility
PressAugust 20, 2024 MindBio Therapeutics Corp. Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials
PressAugust 20, 2024 PharmaDrug’s Sairiyo Therapuetics Receives Approval to Initiate Phase 1 Clinical Trial of Patented Reformulated Cepharanthine
PressAugust 20, 2024 Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
Health & ScienceAugust 19, 2024 MindBio Reports Promising Phase 2A Results for Depression Treatment with LSD
PressAugust 16, 2024 Optimi Health Completes Inaugural Export of MDMA Capsules to Australia for PTSD Treatment
PressAugust 15, 2024 Filament Health Announces Second Quarter 2024 Financial Results and Operational Highlights
